Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FSTX

F-star Therapeutics (FSTX) Stock Price, News & Analysis

F-star Therapeutics logo

About F-star Therapeutics Stock (NASDAQ:FSTX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$4.42
$7.12
52-Week Range
N/A
Volume
N/A
Average Volume
709,213 shs
Market Capitalization
$156.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

Remove Ads
Receive FSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for F-star Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FSTX Stock News Headlines

Astria Therapeutics price target raised to $28 from $26 at Oppenheimer
Lake Street Remains a Buy on Aquestive Therapeutics (AQST)
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
Bicara Therapeutics Rises 39% in Debut on Nasdaq
See More Headlines

FSTX Stock Analysis - Frequently Asked Questions

F-star Therapeutics, Inc. (NASDAQ:FSTX) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.06. The firm had revenue of $0.75 million for the quarter, compared to the consensus estimate of $7.18 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that F-star Therapeutics investors own include New Age Brands (NF), Aurora Cannabis (ACB), Trican Well Service (TCW), Meta Platforms (META), NIO (NIO), Plug Power (PLUG) and Copper Mountain Mining (CMMC).

Company Calendar

Last Earnings
11/10/2021
Today
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FSTX
Employees
84
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-31,280,000.00
Pretax Margin
-213.97%

Debt

Sales & Book Value

Annual Sales
$21.17 million
Price / Cash Flow
N/A
Book Value
$4.70 per share
Price / Book
1.51

Miscellaneous

Free Float
21,279,000
Market Cap
$156.50 million
Optionable
Not Optionable
Beta
0.85
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:FSTX) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners